StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
UTMD$66.18-0.41%
Fair $66.18+0.0%

UTMD

Utah Medical Products, Inc.

Healthcare / Medical Instruments & SuppliesNasdaqGS

$66.18

-0.27 (-0.41%)

Fairly Valued+0.0%Fair Value $66.18Fund rank 39/100 · Data gapFallback financials|
SA 53/C
F-Score: 4/9
Declining RevenueMargin Compression

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $14.6M · quality 86.7/100

Data gap 39/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 85/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

53/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 17Warnings: 2unknown: 17
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 3 consecutive years Operating margin has declined for 4 consecutive years
Thesis & Journal · UTMDLocal privado en este navegador · Utah Medical Products, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$211M

P/E

19.6x

↓

EV/EBITDA

8.9x

↓

ROE

9.5%

↑

Gross Margin

57.1%

↑

Debt/Equity

0.00

↓
52-Week Range$66
$52$72

TradingView lightweight chart

UTMD price, volumen y niveles de valoración

Último $66.18Periodo +928.0%
Fair value: $66.18

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2009–2025 · 16 años de histórico normalizado

Revenue CAGR

+2.5%

FCF CAGR

+4.8%

FCF margin

37.2%

FCF / Net income

1.27x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $38.5M · net income $11.3M · FCF $14.3M

2009-FY → 2025-FY

Gross margin

57.1%+3.9% pts

Operating margin

29.6%-6.8% pts

Net margin

29.3%+5.2% pts

FCF margin

37.2%+11.1% pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Income Statement
Revenue$38.5M$38.5M$40.9M$50.2M$52.3M$49.1M$42.2M$46.9M$42.0M$41.4M$39.3M$40.2M$41.3M$40.5M$41.6M$37.9M$25.1M$25.9M
Net Income$11.3M$11.3M$13.9M$16.6M$16.5M$14.8M$10.8M$14.7M$18.6M$8.5M$12.1M$11.8M$11.4M$11.4M$10.2M$7.4M$6.0M$6.3M
EBITDA$14.4M$14.4M$16.4M$23.1M$26.9M—————————————
EPS3.483.483.964.574.524.042.943.944.952.283.223.143.023.022.742.031.651.72
Gross Margin57.1%57.1%59.0%59.8%61.6%63.0%60.6%62.8%62.6%63.7%60.3%60.2%60.5%59.9%60.9%59.2%52.6%53.2%
Operating Margin29.6%29.6%33.2%33.4%37.9%38.5%32.5%37.6%44.5%45.9%41.2%39.0%39.3%36.6%36.6%31.3%35.5%36.4%
Net Margin29.3%29.3%33.9%33.1%31.5%30.1%25.6%31.4%44.2%20.5%30.9%29.5%27.6%28.2%24.5%19.6%23.9%24.1%
Balance Sheet
Debt/Equity0.000.000.000.000.000.000.000.000.000.00—0.000.000.00————
Current Ratio28.6428.64————————————————
Cash Flow
Free Cash Flow$14.3M$14.3M$14.6M$21.6M$20.3M$20.7M$19.3M$16.5M$16.4M$15.3M$11.2M$13.6M$14.3M$12.0M$13.3M$11.1M$5.6M$6.8M
Returns
ROE9.5%9.5%11.8%13.0%14.4%13.8%10.5%14.6%20.9%10.9%17.5%17.0%17.6%18.8%20.0%18.2%15.9%—
Valuation
P/E19.5819.5815.4917.6821.94—————————————
EV/EBITDA8.948.948.048.7110.67—————————————
P/B1.801.801.832.293.16—————————————
Growth & Yield
Revenue Growth-5.8%-5.8%-18.6%-3.9%—16.3%-10.1%11.7%1.4%5.4%-2.1%-2.7%1.9%-2.5%9.8%50.7%-3.1%—
EPS Growth-12.1%-12.1%-13.4%1.1%—37.4%-25.4%-20.4%117.1%-29.2%2.5%4.0%0.0%10.2%35.0%23.0%-4.1%—
Dividend Yield1.9%1.9%————————————————

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

19.1%

exigente

EPS terminal req.

$5.87

Spread vs growth

-31.2%

5Y implied EPS CAGR

15.3%

exigente

EPS terminal req.

$7.11

Spread vs growth

-27.5%

10Y implied EPS CAGR

12.6%

razonable

EPS terminal req.

$11.44

Spread vs growth

-24.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +22.0%

Total return

+22.0%

Start / end P/E

13.9x → 19.0x

EPS bridge

3.96 → 3.48

Residual

-4.5%

EPS growth-12.1%
Multiple rerating+36.8%
Dividend+1.9%
Residual / FX / buybacks / cross-term-4.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.